High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 601–700 of 1,016
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Applying CRISPR–Cas9 tools to identify and characterize transcriptional enhancers
Lopes, R., Korkmaz, G., & Agami, R. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.79 · Cited by 73
Enhanced specificity mutations perturb allosteric signaling in CRISPR-Cas9
Nierzwicki, Ł., East, K. W., Morzan, U. N., Arantes, P., Batista, V. S., Lisi, G. P., & Palermo, G. (2021) · eLife · doi:10.7554/elife.73601 · Cited by 65
Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Haeussler, M., & Concordet, J. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.04.008 · Cited by 69
Liu, Y., Yang, Y., Kang, X., Lin, B., Qian, Y., Song, B., Gao, G., Chen, Y., Sun, X., Li, X., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.11.010 · Cited by 65
Deep mutational scanning of S. pyogenes Cas9 reveals important functional domains
Spencer, J. M., & Zhang, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-17081-y · Cited by 63
Exosome-mediated horizontal gene transfer occurs in double-strand break repair during genome editing
Ono, R., Yasuhiko, Y., Aisaki, K.-I., Kitajima, S., Kanno, J., & Hirabayashi, Y. (2019) · Communications Biology · doi:10.1038/s42003-019-0300-2 · Cited by 61
Development of a CRISPR/Cas9 System for Methylococcus capsulatus In Vivo Gene Editing
Tapscott, T., Guarnieri, M. T., & Henard, C. A. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.00340-19 · Cited by 67
Structural insights into a high fidelity variant of SpCas9
Guo, M., Ren, K., Zhu, Y., Tang, Z., Wang, Y., Zhang, B., & Huang, Z. (2019) · Cell Research · doi:10.1038/s41422-018-0131-6 · Cited by 65
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
Lattanzi, A., Duguez, S., Moiani, A., Izmiryan, A., Barbon, E., Martin, S., Mamchaoui, K., Mouly, V., Bernardi, F., Mavilio, F., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.004 · Cited by 72
Gene Editing and Genotoxicity: Targeting the Off-Targets
Blattner, G., Cavazza, A., Thrasher, A. J., & Turchiano, G. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.613252 · Cited by 70
“In the same way, the different gene editing strategies are shaping novel reagents, techniques and strategies to improve their safety and efficiency for clinical application (Miller et al., 2007; Kleinstiver et al., 2016; Casini et al., 2018; Gao et al., 2018; Vakulskas et al., 2018; Rai et al., 2020).”
BackgroundCRISPR-Cas9 Gene Editing for Fruit and Vegetable Crops: Strategies and Prospects
Wan, L., Wang, Z., Tang, M., Hong, D., Sun, Y., Ren, J. M., Zhang, N., & Zeng, H. (2021) · Horticulturae · doi:10.3390/horticulturae7070193 · Cited by 74
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 70
“In addition, optimized Cas9 enzyme is also an approach to reduce the off-target effect, including SpCas9-HF1[174] and eSpCas9[175].”
Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2
Sangree, A. K., Griffith, A. L., Szegletes, Z. M., Roy, P., DeWeirdt, P. C., Hegde, M., McGee, A. V., Hanna, R. E., & Doench, J. G. (2022) · Nature Communications · doi:10.1038/s41467-022-28884-7 · Cited by 67
CRISPR/Cas9 Technology for Enhancing Desirable Traits of Fish Species in Aquaculture
Zhu, M., Sumana, S. L., Muhammad, A. M., Falayi, O. C., Shui, Y., Zhang, C., Zhu, J. X., & Su, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179299 · Cited by 77
“For example, the SpCas9-HF1 and eSpCas9 variants have shown reduced non-specific binding and cleavage compared to the wild-type Cas9, thereby improving target specificity in fish species [58].”
BackgroundCas9 cleavage assay for pre-screening of sgRNAs using nicking triggered isothermal amplification
Zhang, K., Deng, R., Li, Y., Zhang, L., & Li, J. (2016) · Chemical Science · doi:10.1039/c6sc01355d · Cited by 65
Myocardial commitment from human pluripotent stem cells: Rapid production of human heart grafts
Garreta, E., de Oñate, L., Fernández-Santos, M. E., Oria, R., Tarantino, C., Climent, A. M., Marco, A., Samitier, M., Martínez, E., Valls-Margarit, M., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.003 · Cited by 63
Ouellet, D. L., Cherif, K., Rousseau, J., & Tremblay, J. P. (2016) · Gene Therapy · doi:10.1038/gt.2016.89 · Cited by 71
Benati, D., Miselli, F., Cocchiarella, F., Patrizi, C., Carretero, M., Baldassarri, S., Ammendola, V., Has, C., Colloca, S., Río, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.024 · Cited by 69
CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge
Lee, C.-H. (2019) · Molecules · doi:10.3390/molecules24071349 · Cited by 66
Novel and emerging biotechnological crop protection approaches
Giudice, G., Moffa, L., Varotto, S., Cardone, M. F., Bergamini, C., Lorenzis, G. D., Velasco, R., Nerva, L., & Chitarra, W. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13605 · Cited by 66
“Moreover, development of Cas variants with improved specificity, such as Cas12a and b (Ming et al., 2020; Schindele and Puchta, 2020), eSpCas9 (Slaymaker et al., 2016), HiFi-Cas9 (Kleinstiver et al., 2016) and HypaCas9 (Ikeda et al., 2019), tried to mitigate the off-target activity and these variants have already been…”
BackgroundHematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Genome Editing by CRISPR /Cas9: A Game Change in the Genetic Manipulation of Protists
Lander, N., Chiurillo, M. Á., & Docampo, R. (2016) · Journal of Eukaryotic Microbiology · doi:10.1111/jeu.12338 · Cited by 69
“…and the high fidelity Cas9 (Cas9-HF) that significantly reduce the possibility of producing genomic off-targeting, have been recently genetically engineered (Kleinstiver et al. 2016; Slaymaker et al. 2016) and most of the CRISPR/ Cas9 systems are now being re-adapted to include such technology.”
BackgroundCRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential
Blenke, E. O., Evers, M. J. W., Mastrobattista, E., & John van der, O. O. S. T. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.002 · Cited by 65
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.023 · Cited by 68
Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9
Choi, G. C. G., Zhou, P., Yuen, C. T. L., Chan, B. K. C., Xu, F., Bao, S., Chu, H. Y., Thean, D., Tan, K., Wong, K. H., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0473-0 · Cited by 63
Self-citationEnhancing gene editing specificity by attenuating DNA cleavage kinetics
Miller, J. C., Patil, D. P., Xia, D. F., Paine, C. B., Fauser, F., Richards, H. W., Shivak, D. A., Bendaña, Y. R., Hinkley, S. J., Scarlott, N. A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0186-z · Cited by 63
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
“These mutations had been previously introduced into SpCas9 to generate the HiFi Cas9 that showed reduced off-target gene editing [78]: off-target editing was significantly reduced, and the on-target base editing activity was slightly altered.”
BackgroundAdenoviral vectors for in vivo delivery of CRISPR-Cas gene editors
Rice-Boucher, P. J., Cui, X., & Curiel, D. T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.003 · Cited by 71
CRISPR/Cas genome editing to optimize pharmacologically active plant natural products
Dey, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105359 · Cited by 64
Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9
Ashok, B., Peppas, N. A., & Wechsler, M. E. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102728 · Cited by 67
CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment
Bonowicz, K., Jerka, D., Piekarska, K., Olagbaju, J., Stapleton, L., Shobowale, M., Bartosiński, A., Łapot, M., Bai, Y., & Gagat, M. (2025) · Cells · doi:10.3390/cells14020131 · Cited by 64
“Through disruption of contacts between the direct hydrogen bonds of 4 residues and the phosphate backbone of the DNA in SpCas9-HF1, a complete lack of off-target events was seen in comparison to wild-type SpCas9 [88].”
Idoko-Akoh, A., Taylor, L., Sang, H., & McGrew, M. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33244-x · Cited by 65
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities
Roy, B., Zhao, J. C., Yang, C., Luo, W., Xiong, T., Li, Y., Fang, X., Gao, G., Singh, C. O., Madsen, L., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00240 · Cited by 66
Caneva, A. D., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., Giacca, M., Kay, M. A., Vlahoviček, K., Zentilin, L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128863 · Cited by 69
Evolution and Application of Genome Editing Techniques for Achieving Food and Nutritional Security
Fiaz, S., Ahmar, S., Saeed, S., Riaz, A., Mora, F., & Jung, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115585 · Cited by 64
Bao, M., Chen, Q., Xu, Z., Jensen, E. C., Liu, C., Waitkus, J., Yuan, X., He, Q., Qin, P., & Du, K. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00530 · Cited by 63
Hu, J. H., Davis, K. M., & Liu, D. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.009 · Cited by 66
Establishment of a highly efficient virus-inducible CRISPR/Cas9 system in insect cells
Dong, Z., Chen, T., Zhang, J., Hu, N., Cao, M.-Y., Dong, F., Jiang, Y., Chen, P., Lu, C., & Pan, M. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.03.009 · Cited by 65
Precision gene editing technology and applications in nephrology
WareJoncas, Z., Campbell, J. M., Martínez‐Gálvez, G., Gendron, W. A. C., Barry, M. A., Harris, P. C., Sussman, C. R., & Ekker, S. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0047-x · Cited by 62
New Insights Into the Long Non-coding RNA SRA: Physiological Functions and Mechanisms of Action
Sheng, L., Ye, L., Zhang, D., Cawthorn, W. P., & Xu, B. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00244 · Cited by 67
Wang, J., Zhang, C., & Feng, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15039 · Cited by 63
Gene Therapy Approach for Intervertebral Disc Degeneration: An Update
Takeoka, Y., Yurube, T., & Nishida, K. (2020) · Neurospine · doi:10.14245/ns.2040042.021 · Cited by 63
Rose, J. C., Popp, N. A., Richardson, C. D., Stephany, J. J., Mathieu, J., Wei, C. T., Corn, J. E., Maly, D. J., & Fowler, D. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16542-9 · Cited by 58
Progress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 63
Cas9 deactivation with photocleavable guide RNAs
Zou, R. S., Liu, Y., Wu, B., & Ha, T. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.007 · Cited by 63
CRISPR system: Discovery, development and off-target detection
Chen, S., Yao, Y., Zhang, Y., & Fan, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109577 · Cited by 60
GO: a functional reporter system to identify and enrich base editing activity
Katti, A., Foronda, M., Zimmerman, J., Diaz, B. J., Zafra, M. P., Goswami, S., & Dow, L. E. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa124 · Cited by 61
Ma, L., Ruan, J., Song, J. W., Wen, L., Yang, D., Zhao, J., Xia, X., Chen, Y. E., Zhang, J., & Xu, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19842-2 · Cited by 61
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 66
Self-citationCRISPR-DIPOFF: an interpretable deep learning approach for CRISPR Cas-9 off-target prediction
Toufikuzzaman, M., Samee, M. A. H., & Rahman, M. S. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbad530 · Cited by 63
Abbasi, A. F., Asim, M. N., & Dengel, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06013-w · Cited by 62
“…al. [139] utilized 7 different off-target activity prediction datasets namely, CIRCLE-seq [182] (contains mismatch, insertion, and deletion off-target sites), protein knockout detection (II/1) [43], Digenome PDH (II/2) [60], II/3 SITE [19] and GUIDE-seq I, II, III (II/4, II/5, II/6) [90, 115, 181].”
Park, A., Hong, P. W.-P., Won, S. T., Thibault, P. A., Vigant, F., Oguntuyo, K. Y., Taft, J. D., & Lee, B. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.57 · Cited by 68
Gene editing in mouse zygotes using the CRISPR/Cas9 system
Wefers, B., Bashir, S., Rossius, J., Wurst, W., & Kühn, R. (2017) · Methods · doi:10.1016/j.ymeth.2017.02.008 · Cited by 70
Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9
Yumlu, S., Stumm, J., Bashir, S., Dreyer, A.-K., Lisowski, P., Danner, E. W., & Kühn, R. (2017) · Methods · doi:10.1016/j.ymeth.2017.05.009 · Cited by 70
Coupling Cas9 to artificial inhibitory domains enhances CRISPR-Cas9 target specificity
Aschenbrenner, S., Kallenberger, S. M., Hoffmann, M. D., Huck, A., Eils, R., & Niopek, D. (2020) · Science Advances · doi:10.1126/sciadv.aay0187 · Cited by 62
Lighting up single-nucleotide variation in situ in single cells and tissues
Zhang, K., Deng, R., Gao, H., Teng, X., & Li, J. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00438f · Cited by 61
PAM-flexible genome editing with an engineered chimeric Cas9
Zhao, L., Koseki, S. R. T., Silverstein, R. A., Amrani, N., Peng, C., Kramme, C., Savic, N., Pacesa, M., Rodríguez, T. C., Stan, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41829-y · Cited by 59
Self-citationCRISPR-based gene expression control for synthetic gene circuits
Santos‐Moreno, J., & Schaerli, Y. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200020 · Cited by 61
ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
Boutin, J., Cappellen, D., Rosier, J., Amintas, S., Dabernat, S., Bedel, A., & Moreau‐Gaudry, F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0120 · Cited by 68
CRISPR/Cas9, a powerful tool to target human herpesviruses
van Diemen, F. R., & Lebbink, R. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12694 · Cited by 60
The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review
Musunuru, K. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1713 · Cited by 67
Diakatou, M., Manes, G., Bocquet, B., Meunier, I., & Kalatzis, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102542 · Cited by 57
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 63
High-fidelity SaCas9 identified by directional screening in human cells
Xie, H., Ge, X., Yang, F., Wang, B., Li, S., Duan, J., Lv, X., Cheng, C., Song, Z., Liu, C., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000747 · Cited by 63
Molecular Dynamics Reveals a DNA-Induced Dynamic Switch Triggering Activation of CRISPR-Cas12a
Saha, A., Arantes, P. R., Hsu, R. V., Narkhede, Y. B., Jínek, M., & Palermo, G. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00929 · Cited by 59
Gutiérrez-Guerrero, A., Abrey-Recalde, M. J., Mangeot, P. E., Costa, C., Bernadin, O., Perian, S., Fusil, F., Froment, G., Martinez-Turtos, A., Krug, A., et al. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.604371 · Cited by 60
Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches
Leal, A., Herreno-Pachón, A., Benincore-Flórez, E., Karunathilaka, A., & Tomatsu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052456 · Cited by 58
Optimizing Systems for Cas9 Expression in Toxoplasma gondii
Markus, B. M., Bell, G. W., Lorenzi, H., & Lourido, S. (2019) · mSphere · doi:10.1128/msphere.00386-19 · Cited by 58
Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing
Rabinowitz, R., & Offen, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.009 · Cited by 62
CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders
Guan, L., Han, Y., Yang, C., Lu, S., Du, J., Li, H., & Lin, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02638-w · Cited by 64
Biology and applications of CRISPR–Cas12 and transposon-associated homologs
Wu, W. Y., Adiego-Pérez, B., & John van der, O. O. S. T. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02485-9 · Cited by 61
A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research
Miano, J. M., Zhu, Q. M., & Lowenstein, C. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.304790 · Cited by 69
Directed Evolution of CRISPR/Cas Systems for Precise Gene Editing
Liu, R., Liang, L., Freed, E. F., & Gill, R. T. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.07.005 · Cited by 60
Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 64
Emerging Strategies in TCR-Engineered T Cells
Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 65
“To reduce the off-target toxicity, high-fi delity CRISPR – Cas9 nuclease has been developed (87), and a recent review has provided many strategies about how to re fi ne the CRISPR/ Cas9 technology for clinical applications (88).”
BackgroundCRISPR-Cas systems: ushering in the new genome editing era
Rojo, F. P., Nyman, R. K. M., Johnson, A. A. T., Pazos-Navarro, M., Ryan, M. H., Erskine, W., & Kaur, P. (2018) · Bioengineered · doi:10.1080/21655979.2018.1470720 · Cited by 64
Lin, M., Yang, Z., Yang, Y., Peng, Y., Li, J., Du, Y., Sun, Q. L., Gao, D., Yuan, Q., Zhou, Y. J., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101359 · Cited by 57
Progress of targeted genome modification approaches in higher plants
Cardi, T., & Stewart, C. N. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1975-1 · Cited by 59
CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery
Luo, J. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.001 · Cited by 60
Genome editing for inborn errors of metabolism: advancing towards the clinic
Schneller, J. L., Lee, C. M., Bao, G., & Venditti, C. P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0798-4 · Cited by 62
CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy
Liu, X., & Zhao, Y. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.04.003 · Cited by 60
CRISPR/Cas9 cleavage efficiency regression through boosting algorithms and Markov sequence profiling
Peng, H., Zheng, Y., Blumenstein, M., Tao, D., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty298 · Cited by 57
“The subsequent problem is whether the sgRNA’s off-target effect is low (Fu et al., 2013; Shen et al., 2014; Kleinstiver et al., 2016).”
BackgroundKlompe, S. E., & Sternberg, S. H. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0012 · Cited by 59
Peng, H., Zheng, Y., Zhao, Z., Liu, T., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty558 · Cited by 53
CRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 63
Ikeda, A., Fujii, W., Sugiura, K., & Naito, K. (2019) · Communications Biology · doi:10.1038/s42003-019-0627-8 · Cited by 57
Computational Tools and Resources Supporting CRISPR-Cas Experiments
Śledziński, P., Nowaczyk, M., & Olejniczak, M. (2020) · Cells · doi:10.3390/cells9051288 · Cited by 61
CRISPR technologies for the treatment of Duchenne muscular dystrophy
Choi, E., & Koo, T. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.002 · Cited by 59
Restoring the p53 ‘Guardian’ Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
Chira, S., Gulei, D., Hajitou, A., & Berindan-Neagoe, I. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.01.014 · Cited by 56
“In this regard, we are proposing a novel Cas9 nuclease with improved specificity, based on a recently described mutant variant of Cas9, named Cas9HF [28], to which a cyclin destruction box (CDB) sequence [29] is fused to the N-termini of Cas9-HF (Figure 1).”
BackgroundStem cell therapy: a revolutionary cure or a pandora's box
Marei, H. E. S. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04334-1 · Cited by 68
“…have improved CRISPR-Cas9 precision and versatility: high-fidelity Cas9 variants, like SpCas9-HF1, have been developed to reduce off-target effects [25]; newer technologies, such as base editing and prime editing, allow single-nucleotide changes without introducing double-strand breaks, improving…”
Using RNA as Molecular Code for Programming Cellular Function
Kushwaha, M., Rostain, W., Prakash, S., Duncan, J. N., & Jaramillo, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00297 · Cited by 61
Bednarski, C., Tomczak, K., Hövel, B. V., Weber, W.-M., & Cathomen, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161072 · Cited by 60
Wang, J., Chen, R., Zhang, R., Ding, S., Zhang, T., Yuan, Q., Guan, G., Chen, X., Zhang, T., Zhuang, H., et al. (2017) · Theranostics · doi:10.7150/thno.18114 · Cited by 58
The Conspicuity of CRISPR-Cpf1 System as a Significant Breakthrough in Genome Editing
Bayat, H., Modarressi, M. H., & Rahimpour, A. (2017) · Current Microbiology · doi:10.1007/s00284-017-1406-8 · Cited by 58
Protein Inhibitors of CRISPR-Cas9
Bondy-Denomy, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00831 · Cited by 56
IRF1 supports DNA binding of STAT1 by promoting its phosphorylation
Zenke, K., Muroi, M., & Tanamoto, K. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12185 · Cited by 60
“0 (Addgene plasmid # 62988) carrying high fidelity Cas9 (Q526A, R661A, Q695A) cDNA.(34,35) The resultant CRIPSR/Cas9 vector targeting Irf1 was transfected into HEK293 cells.”
Seidl, C. I., Fulga, T. A., & Murphy, C. L. (2018) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2018.09.001 · Cited by 57
Emerging applications of gene editing technologies for the development of climate-resilient crops
Chavhan, R. L., Jaybhaye, S. G., Hinge, V. R., Deshmukh, A. S., Shaikh, U. S., Jadhav, P. K., Kadam, U. S., & Hong, J. C. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1524767 · Cited by 55
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.